{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maruta M"],"funding":["MEXT | Japan Society for the Promotion of Science","Uehara Memorial Foundation"],"pagination":["13293"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6746725"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["The development of chimeric antigen receptor (CAR) and bispecific T-cell engager (BiTE) has led to the successful application of cancer immunotherapy. The potential reactivity mediated by CAR- and BiTE-redirected T cells needs to be assessed to facilitate the application of these treatment options to a broader range of patients. Here, we have generated CAR and BiTE possessing the same single chain fragment variable (scFv) specific for the HLA-A2/NY-ESO-1<sub>157-165</sub> complex (A2/NY-ESO-1<sub>157</sub>). Using HLA-A2<sup>+</sup>NY-ESO-1<sup>+</sup> myeloma cells and peptides presented by HLA-A2 molecules as a model, both sets of redirected T cells recognized and killed HLA-A2<sup>+</sup>NY-ESO-1<sup>+</sup> myeloma cells in an A2/NY-ESO-1<sub>157</sub>-specific manner in vitro. Moreove"],"journal":["Scientific reports"],"pubmed_title":["Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy."],"pmcid":["PMC6746725"],"funding_grant_id":["JP16H07025","JP18H02839"],"pubmed_authors":["Saitou T","Takenaka K","Maruta M","Tanimoto K","Ochi T","Fujiwara H","Yasukawa M","Imamura T","Asai H"],"additional_accession":[]},"is_claimable":false,"name":"Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.","description":"The development of chimeric antigen receptor (CAR) and bispecific T-cell engager (BiTE) has led to the successful application of cancer immunotherapy. The potential reactivity mediated by CAR- and BiTE-redirected T cells needs to be assessed to facilitate the application of these treatment options to a broader range of patients. Here, we have generated CAR and BiTE possessing the same single chain fragment variable (scFv) specific for the HLA-A2/NY-ESO-1<sub>157-165</sub> complex (A2/NY-ESO-1<sub>157</sub>). Using HLA-A2<sup>+</sup>NY-ESO-1<sup>+</sup> myeloma cells and peptides presented by HLA-A2 molecules as a model, both sets of redirected T cells recognized and killed HLA-A2<sup>+</sup>NY-ESO-1<sup>+</sup> myeloma cells in an A2/NY-ESO-1<sub>157</sub>-specific manner in vitro. Moreove","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Sep","modification":"2025-04-22T06:17:53.044Z","creation":"2019-10-11T07:05:47Z"},"accession":"S-EPMC6746725","cross_references":{"pubmed":["31527633"],"doi":["10.1038/s41598-019-49834-2"]}}